Shares of Humacyte Inc (HUMA) are trading -7% lower at a price of $3.22 at the time of this writing.

Humacyte Inc has been trading between a 52-week high of $17.45 and a 52-week low of $3.07. The stock has a market cap of $332 Million.

Humacyte, Inc., is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. The Company develops and manufactures acellular tissues to treat a wide range of diseases, injuries and chronic conditions. Humacyte’s initial opportunity, a portfolio of human acellular vessels (HAVs), is currently in late-stage clinical trials targeting multiple vascular applications, including vascular trauma repair, arteriovenous access for hemodialysis, and peripheral arterial disease.

Humacyte Hosting Key Opinion Leader Webinar on Human Acellular Vessels in the Treatment of Vascular Trauma
Wallstreet:Online 07-07-22

Humacyte Announces JAMA Surgery Publication Highlighting Potential of Human Acellular Vessel™ (HAV™) to Expand Vascular Trauma Reconstruction and Bypass Treatment Options
GlobeNewswire 06-29-22

Humacyte Announces JAMA Surgery Publication Highlighting Potential of Human Acellular Vessel (HAV) to Expand Vascular Trauma Reconstruction and Bypass Treatment Options
Wallstreet:Online 06-29-22

Humacyte Provides Update on Patients Treated at Front-Line Hospitals in Ukraine with the Human Acellular Vessel (HAV) for Repair of Vascular Trauma Injuries
Wallstreet:Online 06-21-22

At What Point In Time Would I Choose To Purchase Humacyte Inc. (NASDAQ: HUMA) Stock?
Stocks Register 06-20-22